Summary
Kinetic data for the new antihypertensive agent ketanserin were determined in six healthy subjects after single oral (40 mg) or intravenous (0.15 mg/kg) doses. Plasma protein binding was 94.0±1.8% (mean±SD). Cumulative urinary excretion of unchanged drug was less than 4% within 48 h following the single dose. The maximal plasma level (cmax) of 193±98.2 µg/l occured within 0.5 to 4.0 h after oral intake. The ketanserin plasma level declined biexponentially after oral administration, and triexponentially over the 36 h following intravenous injection. The terminal elimination half-life (term. t1/2) averaged 12.4±2.9 h and 12.8±4.8 h following oral and intravenous application, respectively. Total plasma clearance was 410±62.0 (i.v.) and 829±228 ml/min (p.o.) and the intravenous blood clearance averaged 602±91 ml/min, which indicates partly flowdependent hepatic elimination. A substantial first-pass effect led to a bioavailability of about 50% (range: 27–69%). Hepatic clearance of ketanserin followed the non-restrictive pattern. No change in blood pressure or heart rate was observed following ketanserin administration to normal volunteers.
Similar content being viewed by others
References
De Cree J, Leempoels J, De Cock W, Geukens H, Verhaegen H (1981) The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R41468) in elderly patients. Angiology 32: 137–144
De Cree J, Verhaegen H, Symoens J (1981). Acute blood pressure lowering effect of ketanserin. Lancet 1: 1161–1162
Wenting GJ, Man In't Veld AJ, Woittiez AJ, Boomsma F, Schalekamp MADH (1982) Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. Br Med J 284: 537–539
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci 28: 1015–1022
Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneur R, Verbeuren TJ, Vanhoutte PM (1981) Vascular effects of R 41468, a novel antagonist of 5-HT serotonergic receptors. J Pharmacol Exp Ther 218: 217–230
Kalkman HO (1982) The antihypertensive effect of the new serotonin antagonist ketanserin in the rat is probably due to antagonism of vascular a1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmocol 319 [Suppl]: R 50
Fozard JR (1982) Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838
Janssen Pharmaceutica (1982) Ketanserin. The first pure and selective 5-HT2-receptor blocking agent. Investigational New Drug Brochure, 6th edition
Okonkwo PO, Reimann IW, Woestenborghs R, Klotz U (1983) High performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr (Biomed Appl) 272: 411–416
Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074
Castleman PA, Russell DH, Webb FN, Hollister CA, Siege JR, Zdonik SR, Fram DM (1974) The implementation of the PRO-PHET system. Natl Comput Conf Exp Proc 43: 457–468
Reimann JW, Frölich JC (1983) Is Ketanserin a D receptor antagonist? Lancet 1: 703–704
Author information
Authors and Affiliations
Additional information
On leave from the Department of Pharmacology and Therapeutics, University of Nigeria, Enugu, Nigeria, Africa
Rights and permissions
About this article
Cite this article
Reimann, I.W., Okonkwo, P.O. & Klotz, U. Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol 25, 73–76 (1983). https://doi.org/10.1007/BF00544018
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544018